NURO — NeuroMetrix Share Price
0.000.00%
Last trade - 00:00- $8.94m
- -$4.16m
- $3.03m
- 20
- 42
- 82
- 46
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.62 | ||
| Price to Tang. Book | 0.62 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.95 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -61.36% | ||
| Return on Equity | -45.38% | ||
| Operating Margin | -289.56% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 7.38 | 8.25 | 8.26 | 5.9 | 3.03 | n/a | n/a | -20.03% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.
Directors
- Shai Gozani CHM (56)
- Thomas Higgins CFO (69)
- David Goodman IND (64)
- Nancy Katz IND (62)
- David Van Avermaete IND (69)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 25th, 2001
- Public Since
- July 22nd, 2004
- No. of Shareholders
- 40
- No. of Employees
- 13
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 2,059,693
- Address
- 1000 Winter Street, WALTHAM, 02451
- Web
- https://www.neurometrix.com/
- Phone
- +1 7818909989
- Auditors
- BAKER TILLY US LLP
Upcoming Events for NURO
Q1 2025 NeuroMetrix Inc Earnings Release
Q2 2025 NeuroMetrix Inc Earnings Release
Similar to NURO
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the NeuroMetrix share price?
As of Today at 22:14 UTC, shares in NeuroMetrix are trading at $4.34. This share price information is delayed by 15 minutes.
How has the NeuroMetrix share price performed this year?
Shares in NeuroMetrix last closed at $4.34 and the price had moved by -1.59% over the past 365 days. In terms of relative price strength the NeuroMetrix share price has underperformed the S&P500 Index by -9.16% over the past year.
What are the analyst and broker recommendations for NeuroMetrix?
The overall consensus recommendation for NeuroMetrix is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the NeuroMetrix dividend yield?
NeuroMetrix does not currently pay a dividend.
Does NeuroMetrix pay a dividend?
NeuroMetrix does not currently pay a dividend.
When does NeuroMetrix next pay dividends?
NeuroMetrix does not currently pay a dividend.
How do I buy NeuroMetrix shares?
To buy shares in NeuroMetrix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of NeuroMetrix?
As of the previous close price of $4.34, shares in NeuroMetrix had a market capitalisation of $8.94m.
Where are NeuroMetrix shares listed?
Here are the trading details for NeuroMetrix:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NURO
What kind of share is NeuroMetrix?
Based on an overall assessment of its quality, value and momentum NeuroMetrix is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a NeuroMetrix share price forecast for 2025?
The analyst consensus target price for shares in NeuroMetrix is $50.00. That is 1052.07% above the last closing price of $4.34.
Analysts covering NeuroMetrix currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the NeuroMetrix share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NeuroMetrix. Over the past six months, its share price has outperformed the S&P500 Index by +12.95%.
As of the last closing price of $4.34, shares in NeuroMetrix were trading +7.61% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the NeuroMetrix PE Ratio?
The NeuroMetrix PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.34.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of NeuroMetrix?
NeuroMetrix's management team is headed by:
- Shai Gozani - CHM
- Thomas Higgins - CFO
- David Goodman - IND
- Nancy Katz - IND
- David Van Avermaete - IND